We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Sonic Beam Therapy Liquefies Tumor Tissues

By MedImaging International staff writers
Posted on 01 Nov 2021
Print article
Image: The Edison histotripsy sonic beam platform (Photo courtesy of Histonics)
Image: The Edison histotripsy sonic beam platform (Photo courtesy of Histonics)
An automated external beam system uses acoustic energy to mechanically destroy tissue in the liver without incisions, ionizing radiation, or heat.

The HistoSonics (Minneapolis, MN, USA) Edison is a sophisticated histotripsy sonic beam platform designed to deliver pulsed sound energy into the body, without any incisions or needles, that destroys tissue at the sub-cellular level. Physicians first contour and plan treatment according to shape and size of their target; once the energy required to initiate cellular destruction is determined, the acoustic pulses are delivered. Treatment is monitored in real-time, while the system automatically moves through the target area.

Histotripsy uses pulsed sound waves to induce microbubbles from gases that are naturally present in tissues. These “bubble clouds” form and collapse in microseconds, creating mechanical forces that are strong enough to destroy tissue in a non-invasive and non-thermal method. As only 20%-30% of patients with liver tumors are eligible for surgical resection, due to the presence of multiple tumors, underlying poor liver function, or general health issues, histotripsy may provide a solution. Edison has received breakthrough device designation from the U.S. Food and Drug Administration (FDA).

“The Breakthrough Device Designation is a significant milestone for our company and validates our belief that our platform offers significant advantages over existing approved or cleared alternatives,” said Mike Blue, President and CEO of HistoSonics. “Early and ongoing clinical results are promising and suggest that our ability to precisely destroy targeted liver tissue, completely non-invasively, and without the challenges associated with ionizing radiation or other locoregional therapies, provides advantages to patients and physicians that don't exist today.”

Primary liver tumors were the third leading cause of tumor related death worldwide in 2020, with approximately 906,000 new cases and 830,000 deaths globally, and 5-year survival rates less than 18%. Additionally, the liver is second only to lymph nodes as the most common site of metastatic tumors, and estimated to be present in up to 70% of patients with advanced disease from another site.

Related Links:
HistoSonics


Print article
Radcal
Radcal

Channels

Radiography

view channel
Image: The Definium 656 HD is the company’s most advanced fixed X-ray system yet (Photo courtesy of GE Healthcare)

Next-Gen X-Ray System Brings ‘Personal Assistant’ to Radiology Departments

X-ray imaging often provides the entry point to diagnostic imaging - accounting for 60% of all imaging studies conducted. As a result, X-ray technologists, radiologists and radiology administrators are... Read more

Ultrasound

view channel
Image: The new device can better measure blood flow and oxygenation in the placenta (Photo courtesy of University of Pennsylvania)

Novel Method Combines Optical Measurements with Ultrasound for Monitoring ‘Engine’ of Pregnancy

The placenta, considered as the “engine” of pregnancy, is an organ that plays a crucial role in delivering nutrients and oxygen to the fetus. Placental dysfunction can lead to complications such as fetal... Read more

General/Advanced Imaging

view channel
Image: Radiologists would prefer AI-based decision support during screening mammography interpretation (Photo courtesy of Pexels)

Most Radiologists Want to Adopt AI Tools into Clinical Practice, Finds Study

Artificial intelligence (AI) may improve cancer detection and risk prediction during mammography screening, but radiologists’ preferences regarding its characteristics and implementation are unknown.... Read more

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.